Core Viewpoint - The successful stem cell transplant of a 7-year-old Vietnamese thalassemia patient marks a significant achievement in cross-border healthcare collaboration between Guangxi, China, and four provinces in Vietnam [1][3]. Group 1: Project Overview - The "Severe Thalassemia Treatment Project" initiated on May 20, 2023, is a collaboration between the Guangxi Health Commission, the Guangxi Red Cross, and the health departments of four Vietnamese border provinces [3]. - Guangxi Medical University First Affiliated Hospital is the core medical unit for this project, leveraging its expertise in thalassemia prevention and treatment [3][4]. Group 2: Patient Treatment Details - The patient, referred to as "Little Candy," underwent a half-matched unrelated donor stem cell transplant, which is more challenging than a fully matched transplant due to higher risks of complications [3][4]. - Little Candy was admitted to the China-ASEAN Medical Cooperation Center on September 14, 2023, and successfully navigated critical phases of treatment, including bone marrow suppression and infection peaks [4]. Group 3: Treatment Outcomes - After 67 days of treatment, Little Candy's hematopoietic function has largely recovered, she no longer requires blood transfusions, and has not experienced any rejection or complications [1][4].